Aldevron News / Aldevron

WEBINAR: CRISPR Genome Editing Solutions from Discovery to Clinic

Among current techniques for clinical genome editing, the CRISPR-associated gene editing system has emerged as a highly advantageous method to drive development of new gene and cell therapies. Through evolving routes of direct delivery of the CRISPR-ribonucleoprotein (RNP) complex, consisting of single guide RNA (sgRNA) and Cas nucleases, a non-viral approach has become increasingly in demand for gene-editing clinical trials. However, drug developers face significant challenges when initiating their clinical programs, which includes the design and production of the target-specific guides, the production of reliable, high-quality nucleases, and the ability to characterize the RNP complex for the efficient and safe delivery of a genomic therapy.
Read More

WEBINAR: CRISPR Cures 2033: Expanding the Public Health Impact of Gene Editing

In this live webinar, one of the pioneers of human genome editing—Dr. Fyodor Urnov—will lay out the urgent challenge facing the clinical genome editing community in terms of expanding the public health impact of CRISPR-Cas. A formidable financial, logistical, and regulatory hurdle in all genetic therapies is attaining scalable clinic-grade manufacture of the experimental therapeutic. The current costs, timelines, and requirements in that space make the vast majority of genetic disease intractable in a practical sense.  
Read More

Jennifer Meade Named President

FARGO, N.D. (September 11, 2023) – Jennifer Meade has been named President of Aldevron, effective September 11th 2023, as part of a planned leadership transition. She replaces Kevin Ballinger, who has departed Aldevron after leading the organization for three years.

Read More

Aldevron Signs Licensing Agreement With Genentech

Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA, and proteins for the biotech industry, signed a licensing agreement with Genentech, a member of the Roche Group, to use Aldevron’s proprietary Nanoplasmid® vector technology.

Read More

Aldevron, Jennifer Doudna, and Innovative Genomics Institute Collaborate on In Vivo CRISPR Therapies for Neurologic Diseases. Resulting paper published in Molecular Therapy.

FARGO, N.D. (August 29, 2023)Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, contributed to a publication in collaboration with 2020 Nobel Laureate Jennifer Doudna and the Innovative Genomics Institute (IGI) at the University of California, Berkeley to advance research on in vivo, CRISPR-based genome editing strategies to address genetic diseases of the central nervous system such as Huntington’s disease and ALS. Aldevron supplied custom CRISPR protein with ultra-low endotoxin, enabling direct delivery to the brain in mice. This partnership resulted in a paper, titled “Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs,” published in the journal Molecular Therapy, the official journal of the American Society of Gene and Cell Therapy.

Read More

Webinar: Comprehensive GMP Manufacturing of mRNA-LNP Drug Products: Sequence-to-Vial

The manufacture and release of mRNA therapeutics and vaccines is a complex and challenging process requiring a high degree of expertise, capabilities, and experience. The development and manufacturing of drug product involves several stages that include production of cell banks, linear DNA, and mRNA drug substance, with lipid nanoparticle (LNP) formulation/encapsulation and analytical testing at all steps, through aseptic fill/finish.

Read More